Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Colombiana de Cancerología
Print version ISSN 0123-9015
Abstract
CACERES, Camilo; URIBE, Maria; RUA, Catalina and GONZALEZ, Diego M.. Atypical femur fractures, a rare adverse event of bisphosphonates in oncology: Case report. rev.colomb.cancerol. [online]. 2021, vol.25, n.3, pp.172-177. Epub May 25, 2022. ISSN 0123-9015. https://doi.org/10.35509/01239015.716.
Bisphosphonates are one of the fundamental pillars in the treatment of bone morbidities in patients with different types of solid tumors.1-3 However, despite the experience that we have accumulated during decades, there are adverse events such as atypical fractures (AF) that due to their low frequency can go unnoticed and might not receive adequate management. There are few reports in the literature about AF in cancer treatments. We present a case of a patient with metachronous breast cancer and bone metastases at initial diagnosis, currently in remission, who presents AF of the femur after receiving bisphosphonates for 8 years.
Keywords : atypical fractures; bisphosphonates; bone morbidity; cancer.